Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · Universitat de Barcelona
Abstract
Staging and treatment indication are relevant topics in the management of patients with hepatocellular carcinoma (HCC) and for optimal results, they have to take into account liver function, tumor stage, and physical status. For any staging system to be meaningful it has to link staging with treatment indication; this should be based on robust scientific data. Currently, the sole proposal that serves both aims is the Barcelona Clinic Liver Cancer (BCLC) approach. It takes into account the relevant parameters of all important dimensions and divides patients into very early/early, intermediate, advanced, and end-stage. Early-stage HCC patients should be considered for potentially curative options such as…
Citation impact
- FWCI
- 27.99
- Percentile
- 100%
- References
- 0
Authors
4- AFAlejandro FornerCorresponding
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
- MRMaría Reig
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
- CRCarlos Rodríguez de Lope
Universitat de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
- JBJordi Bruix
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
Topics & keywords
- Sorafenib
- Stage (stratigraphy)
- Medicine
- Hepatocellular carcinoma
- Liver transplantation
- Liver cancer
- Curative treatment
- Radiofrequency ablation
- Good health and well-being